Asset Details
Do you wish to reserve the book?
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Do you wish to request the book?
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
2024
Overview
This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
